ARS Pharmaceuticals Hits 52-Week Low at $9.34 Amid Financial Struggles

ARS Pharmaceuticals, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 9.34 on September 25, 2025. This significant decline marks a stark contrast to its 52-week high of USD 18.90, highlighting the volatility the stock has experienced over the past year.
The company's performance metrics reveal a challenging landscape. Over the last year, ARS Pharmaceuticals has generated a return of -29.61%, significantly underperforming the S&P 500, which has seen returns of 15.79%. The company reported negative results in March 2025, breaking a streak of three consecutive positive quarters. Key indicators such as Return on Equity (ROE) stand at -24.97%, and the Return on Capital Employed (ROCE) is at its lowest at -23.56%.

Additionally, the company faces rising raw material costs, which have increased by 29.47% year-over-year, contributing to an operating profit of USD -47.33 million. With a market capitalization of USD 1,057 million, ARS Pharmaceuticals continues to navigate a challenging financial environment, as reflected in its current stock performance.